What Is Sapropterin and How Does It Work?
Sapropterin (Kuvan) is a synthetic form of tetrahydrobiopterin (BH4), a cofactor that enhances phenylalanine hydroxylase activity in phenylketonuria (PKU) patients. It lowers blood phenylalanine (Phe) levels in responsive patients by improving Phe metabolism.[1]
What Counts as an Initial Response?
Clinicians define initial response as a ≥30% reduction in blood Phe levels within 4 weeks of starting therapy, typically at doses of 10-20 mg/kg/day. Testing involves a 2-week drug washout, baseline Phe measurement, then 1 week at 10 mg/kg/day followed by 1 week at 20 mg/kg/day. Responders continue; non-responders stop.[1][2]
How Quickly Does Response Happen?
Blood Phe drops within hours to days in responders, with peak effects by 4 weeks. About 20-50% of PKU patients respond, higher in mild/moderate cases (Phe 360-1200 μmol/L).[1][3]
Who Responds Best?
- Children under 6 years: up to 68% response rate.
- Mild hyperphenylalaninemia: 44-79%.
- Classic PKU: lower rates (10-20%).
Genotype predicts response; mutations allowing residual enzyme activity correlate with success.[2][3]
What If There's No Response?
Non-responders (no 30% drop) discontinue after 4 weeks. Re-testing possible later, as response can emerge with age or diet changes. Long-term non-response occurs in ~50%.[1][2]
Common Side Effects During Initial Therapy
Mild issues include headache (13%), runny nose (12%), sore throat (7%), and cough. Rare: hypersensitivity or Phe elevation. Monitor weekly blood Phe.[1]
[1]: Kuvan Prescribing Information
[2]: BioMarin Patient Resources
[3]: Vockley J, et al. Mol Genet Metab. 2014;112(1):20-33. PubMed